Stock Financial Ratios, Dividends, Split History

EQGP / EQT GP Holdings LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)6,143.09
Enterprise Value ($M)9,302.37
Book Value ($M)2,202.43
Book Value / Share8.27
Price / Book2.86
NCAV ($M)-1,343.79
NCAV / Share-5.05
Price / NCAV-4.85
Share Statistics
Common Shares Outstanding 266,165,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.26
Return on Assets (ROA)0.18
Return on Equity (ROE)0.29
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.89
Income Statement (mra) ($M)
Gas Gathering Transportation Marketing And Processing Revenue834,096,000.00
Operating Income577.69
Net Income568.92
Cash Flow Statement (mra) ($M)
Cash From Operations647.83
Cash from Investing-456.97
Cash from Financing-456.97
Identifiers and Descriptors
Central Index Key (CIK)1632933
Related CUSIPS
26885J903 26885J953

Split History

Stock splits are used by EQT GP Holdings LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Master Limited Partnership Simplifications On The Rise

2018-05-18 seekingalpha
The three only mark an acceleration of the trend of MLP "roll-ups," however. Many others have been announced in 2018. (43-0)

'Safer' Dividend Energy WallStars Feature Midstream May Target Gains

2018-05-17 seekingalpha
Energy firms with at least 0.71 broker target upside and 2% dividend yield made a list of 90 high yield WallStars. (9-0)

Are MLPs Really Disappearing?

2018-04-25 seekingalpha
There's a common impression (dare we say, misconception?) in the MLP space that MLPs are becoming endangered species - in other words, that MLPs are on a path to extinction. Yes, there have been restructuring announcements and conversions to C Corporations, and certainly, the space is evolving. We will probably see more restructurings of MLPs that result in a conversion to a C-Corp structure. That said, it's probably premature to make the call that we are going to see a wholesale abandonment of the MLP model. (38-0)

'Safer' Dividend Energy Equities Trail Shell Midstream's March Target Gains

2018-04-02 seekingalpha
Broker top-ten net-gain "Safer" dividend energy March stocks (per 1yr. targets) were HEP, DCP, EP, EQGP, GLOP, GPP, VLP, EQM, TEGP, & led by SHLX with 21.6%-55.45% gains. (11-0)

Dividend Sensei's Portfolio Update 26: Let The Next Market Crash Make You Rich

2018-03-13 seekingalpha
The bull market just turned nine, but history and positive fundamentals indicate that it might have many more years to run. (172-3)

CUSIP: 26885J103